Th17 cells and aplastic anemia.
10.7534/j.issn.1009-2137.2014.05.053
- Author:
Hai-Yan ZHANG
1
;
Wu WEI
2
;
Xu-Liang SHEN
3
Author Information
1. The First Clinical College, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
2. Department of Hematology, Peace Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi Province, China. E-mail: weiwu88@sohu.com.
3. Department of Hematology, Peace Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi Province, China.
- Publication Type:Journal Article
- MeSH:
Anemia, Aplastic;
immunology;
Autoimmune Diseases;
Cell Differentiation;
Cytokines;
Humans;
Inflammation;
Th17 Cells;
cytology;
immunology
- From:
Journal of Experimental Hematology
2014;22(5):1463-1466
- CountryChina
- Language:Chinese
-
Abstract:
During the past few years, a novel family of CD4⁺T cell lineage was detected and named as Th17 cells because of its unique ability expressing IL-17, which also can produce IL-17A, IL-17F, IL-21, IL-22 and IL-26. Some cytokines, such as TGF-β, IL-6, L-23 may promote the differentiation of Th17 subset, whereas some cytokines, such as IL-21, IL-2, IFN-γ, may have inhibitory effects. Th17 cells serving as immune effectors play an important role in autoimmune diseases caused by chronic inflammation injury. More and more studies confirmed that Th17 cells have closely correlations with the development of aplastic anemia, and may be a new target in the diagnosis, therapy, prognosis and prophylaxis of aplastic anemia.
